Market Overview

UPDATE: Jefferies Raises PT on AbbVie on Attractive Valuation

Share:
Related
Ira Sohn Conference Live Blog: Movers, Shakers, Hedgie Comments
AbbVie Beats Q1 Views, Raises Earnings Outlook
Pharmacyclics Beats on Q1 Earnings, Misses Revenues - Analyst Blog (Zacks)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), and raised the price target from $45.00 to $50.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

AbbVie closed on Tuesday at $42.55.

Latest Ratings for ABBV

DateFirmActionFromTo
Apr 2015BMO CapitalMaintainsOutperform
Apr 2015BMO CapitalUpgradesMarket PerformOutperform
Feb 2015CitigroupInitiates Coverage onSell

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABBV)

Around the Web, We're Loving...

Get Benzinga's Newsletters